October 11 - 15, 2023
CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI)
Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study
Antimicrobial Activity of Cefepime in Combination 2122 Palmer Drive with Taniborbactam Against Resistant Clinical Isolates from the United States 2018-2021
Ceftibuten-Ledaborbactam Etzadroxil: Addressing the Need for an Oral Antibiotic to Treat Drug Resistant Enterobacterales
September 19 - 22, 2023
Susceptibility Profiles of Baseline Gram-negative Pathogens from CERTAIN-1, a Phase 3 Study comparing Cefepime-taniborbactam to Meropenem in Adultswith Complicated Urinary Tract Infection (cUTI)
ASM Microbe 2023
July 20, 2023
Validation of Cefepime-Taniborbactam MIC Antimicrobial Susceptibility Test for MicroScan Dried Gram-Negative MIC Panels from a Multicenter Assessment of Enterobacterales and
April 15 - 18, 2023
Activity of Cefepime-Taniborbactam (FTB) Against Enterobacterales and P. aeruginosa Collected Globally in 2018-2021 Stratified by β-lactamase Carriage
Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Isolates of Enterobacterales from 2018-2021 Global Surveillance
October 19 - 23, 2022
Activities of Cefepime-Taniborbactam and Ceftazidime-Avibactam against Cefepime-Resistant Respiratory Gram-Negative Pathogens in a Hollow Fiber Infection Model
Development of Cefepime-Taniborbactam MIC Antimicrobial Susceptibility Test for Gram-Negative Bacteria on MicroScan Dried Gram-Negative MIC Panels
Antimicrobial Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates from ICU and Non-ICU Patients; 2018-2020 Global Surveillance
Cefepime -Taniborbactam: Addressing Current and Future Antimicrobial Resistance
A phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)
ASM Microbe 2022
October 12, 2022
Structural insights into potent inhibition of PDC-3 and PDC-88 β-lactamases by the bicyclic boronic acid inhibitor taniborbactam
October 4 - 7, 2022
April 23 - 26, 2022
P0633 - Antimicrobial activity of cefepime in combination with taniborbactam against resistant clinical isolates of Enterobacterales from 2018-2020 global surveillance
September 29 - October 3, 2021
Oral Presentation 133 – ARGONAUT-III: Susceptibility of Carbapenem-resistant Klebsiellae to Cefepime-Taniborbactam
Poster Presentation 642 – Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A multicenter evaluation
Poster Presentation 1055 – ARGONAUT-IV: Susceptibility of Carbapenem-resistant Klebsiellae to Ceftibuten/VNRX-5236
Poster Presentation 1253 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from 2018-2020 Global Surveillance
Poster Presentation #1286 – Taniborbactam Inhibits Cefepime-Hydrolyzing Variants of Pseudomonas-derived Cephalosporinase (PDC)
Poster Presentation 1293 – In vitro Activity of Ceftibuten in Combination with VNRX-5236 against Clinical Isolates of Enterobacterales from Urinary Tract Infections Collected in 2018-2020
July 9 - 12, 2021
Abstract 02128 – Cefepime-taniborbactam (formerly cefepime/VNRX-5133) demonstrates potent activity vs. Enterobacterales with blaOXA-48
Abstract 02144 – Examining the antimicrobial activity of cefepime-taniborbactam (formerly cefepime/VNRX-5133) against Burkholderia species isolated from cystic fibrosis patients in the United States
Abstract 02564 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against a European 2018-2020 Surveillance Collection of Pseudomonas aeruginosa
Abstract 02581 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from Europe Collected from 2018-2020 Surveillance
Abstract 03198 – Evaluation of the in vitro activity of cefepime-taniborbactam against carbapenemase-producing Enterobacterales recovered in Spain
Abstract 03200 – Exploring the in vitro activity of cefepime/taniborbactam combination against metallo beta-lactamase producing Klebsiella pneumoniae and Pseudomonas aeruginosa isolates
Abstract 03285 – Assessment of activity of a novel orally bioavailable β-lactam/β-lactamase inhibitor combination, ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) against Enterobacterales carrying blaOXA-48
Abstract 03578 – Activity of cefepime-taniborbactam (formerly cefepime/VNRX-5133) and comparators against NDM-producing Enterobacterales from a regional outbreak
International Liver Congress 2021
June 23 - 26, 2021
Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of chronic hepatitis B virus (HBV) infection
World Microbe Forum 2021
June 20 - 24, 2021
Association of Cefepime-Taniborbactam MICs and β-lactam Resistance Mechanisms Identified Using Whole Genome Sequencing of Ertapenem-nonsusceptible Enterobacterales Clinical Isolates: CANWARD 2007-2018
October 21 - 25, 2020
Poster 1263 - Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-Beta-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in a Hollow Fiber Infection Model (HFIM)
Poster 1318 - Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
April 18 - 21, 2020
P0284 – A multi-site study comparing a commercially-prepared dried MIC susceptibility system to the CLSI/ISO broth microdilution method for cefepime-taniborbactam (formerly cefepime/VNRX-5133) using Gram-negative non-fastidious organisms
P2737 - Antimicrobial Activity of Cefepime in Combination with Taniborbactam(formerly VNRX-5133) against a European 2018-2019 Surveillance Collection of Pseudomonas aeruginosa
P2738 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from Europe Collected from 2018-2019 Surveillance
ASM Microbe 2019
June 23, 2019
SUNDAY - AAR-719 - Rescue of Ceftibuten Activity by the Oral Beta-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D Beta-Lactamases
SUNDAY - AAR-720 - The Orally Bioavailable Beta-Lactamase Inhibitor VNRX-7145 Restores Bactericidal Activity of Ceftibuten against Enterobacteriaceae Expressing Ambler Class A, C, and/or D Enzymes.
SUNDAY - AAR-722 - Antimicrobial Activity of Cefepime in Combination with VNRX-5133 against a Global 2018 Surveillance Collection of
SUNDAY - AAR-723 - Synergy/Antagonism of Ceftibuten/VNRX-7145 in Combination with Other Commonly Used Antimicrobial Agents in Gram-Negative Aerobic Bacteria, Anaerobic Bacteria, and Yeast.
SUNDAY - AAR-726 - Efficacy of Ceftibuten + VNRX-7145, a Novel Beta-Lactamase Inhibitor against ESBL E. coli Strains in a Murine UTI Model
SUNDAY - AAR-727 - Assessment of the In Vivo Pharmacodynamic Profile of Ceftibuten (CTB)/VNRX-7145 Combination against Serine β-Lactamase-Producing Enterobacteriaceae (SBL-EB) in the Neutropenic Murine Thigh Infection Model
SUNDAY - AAR-728 - Oral Bioavailability of Novel Beta-Lactamase Inhibitor VNRX-7145 in Rats, Dogs and Non-Human Primates
SUNDAY - CPHM-860 - Impact of Variations in Susceptibility Testing Parameters on the In Vitro Activity of Ceftibuten in Combination with VNRX-7145 ECCMID 2019
April 13 - 16, 2019
#P1175 — Antimicrobial activity of cefepime in combination with VNRX-5133 against a global 2018 surveillance collection of clinical isolates.
#P1176 — Antimicrobial activity of cefepime in combination with VNRX-5133 against a collection of beta-lactamase-producing Enterobacteriaceae.
#P1178 — VNRX-5133 maintains potent inhibitory activity in engineered NDM-1 variants with increased cefepime hydrolytic efficiency.
#P1179 — Evaluation of the in vitro activity of cefepime plus VNRX-5133 and comparative agents against carbapenem-resistant Enterobacteriaceae.
#P1181 — Selection of ceftibuten as the partner antibiotic for the oral beta-lactamase inhibitor VNRX-7145.
#P1182 — Ceftibuten/VNRX-7145, an orally bioavailable beta-lactam/beta-lactamase inhibitor combination active against serine-beta-lactamase producing Enterobacteriaceae.
#P1951 — Pharmacokinetics of VNRX-5133 in Combination with Cefepime and Metronidazole.
October 3 - 7, 2018
Poster 1360 – Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes.
K. pneumoniae and P. aeruginosa.
Poster 1370 – Cefepime/VNRX-5133 Broad-Spectrum Activity is Maintained against Emerging KPC- and PDC-Variants in Multidrug Resistant
Poster 1395 – Defining the Magnitude of AUC:MIC Driver for Efficacy of the beta-lactamase Inhibitor VNRX-5133 when combined with Cefepime against KPC- and VIM/NDM-producing Enterobacteriaceae and
Poster 1401 – A Randomized, Double-blind, Placebo-controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects.
Poster 1405 – Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination against Serine beta-lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model.
ASM Microbe 2018
June 7 - 11, 2018
FRIDAY 226 — Development of CLSI MIC and disk diffusion quality control ranges for Cefepime/VNRX-5133.
FRIDAY 610 — Cefepime/VNRX-5133 retains potent activity against KPC variants responsible for recent clinical treatment failures of Ceftazidime/Avibactam in
FRIDAY 611 — Evaluation of the Impact of Variation in Standard Testing Parameters on the Activity of Cefepime in Combination with VNRX-5133.
E. coli in a murine UTI model
FRIDAY 612 — Efficacy of cefepime combined with VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, against a cephalosporin-resistant ESBL
April 21 - 24, 2018
#O0575 — Pharmacodynamics of the novel broad-spectrum beta-lactamase inhibitor VNRX-5133 in combination with cefepime in neutropenic female CD-1 mice with experimental pneumonia.
#O0603 — Structural basis for serine- and metallo-beta-lactamase inhibition by VNRX-5133, a new beta-lactamase inhibitor (BLI) in clinical development.
#O0606 — Kinetic mechanism and parameters of inhibition of serine KPC-2, CTX-M15, p99 AmpC and metallo VIM-2 by the broad-spectrum beta-lactamase inhibitor VNRX-5133.
#P1536 — Potentiation of cefepime by the boronate VNRX-5133 versus gram-negative bacteria with known beta-lactamases.
in vitro infection model.
#P1537 — Pharmacokinetics-pharmacodynamics (PK-PD) of VNRX-5133, a broad-spectrum novel beta-lactamase inhibitor (BS-BLI), in combination with cefepime in a one-compartment
#P1538 — Efficacy of cefepime / VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, in a murine bacteremia infection model with carbapenem-resistant Enterobacteriaceae (CREs).
#P1541 | Susceptibility to cefepime / VNRX-5133 in 298 carbapenem-resistant Enterobacteriaceae producing serine- and metallo-beta-lactamases.
#P1543 | Antimicrobial activity of cefepime in combination with VNRX-5133 against a global collection of clinical isolates.